This study aims to evaluate the effectiveness of a single HA injection in improving pain, function, and quality of life in patients with knee OA over a 12-month period. By focusing on a single-arm open-label design, this study will provide practical insights into the real-world application of this treatment approach.
Inclusion Criteria:
i. Adults aged 40-75 years with a clinical and radiographic diagnosis of knee OA (Kellgren-Lawrence grade II-III).
ii. Persistent knee pain (≥4 on a 10-point Visual Analogue Scale [VAS]) for at least 3 months.
iii. Failure to achieve adequate pain relief with conservative treatments (e.g., NSAIDs, physical therapy).
iv. Willingness to provide informed consent and comply with study procedures.
Exclusion Criteria:
i. Severe OA (Kellgren-Lawrence grade IV). ii. History of knee surgery or HA injection within the past 6 months. iii. Inflammatory arthritis (e.g., rheumatoid arthritis, gout). iv. Contraindications to HA injections (e.g., infection, allergy to HA products).
v. Significant comorbidities that may interfere with study participation (e.g., uncontrolled diabetes, morbid obesity, severe cardiovascular disease).
sassidharen6@gmail.com
Treatment Arm will receive a single HA injection to reduce pain and improving knee function in patients with knee OA over 12 months. Outcomes will be assessed, including pain (VAS), function (WOMAC), and safety ( adverse events)
amrankb@usm.my+60 12-900 9272